Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05093062
Other study ID # HHSRF 12133081
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2015
Est. completion date August 31, 2021

Study information

Verified date November 2022
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objectives: To further evaluate the immediate, long-term and cumulative effects of Tian Jiu Therapy on asthma. Hypothesis to be tested: The efficacy of Tian Jiu Therapy on asthma is also long-term and will be accumulated. Design and Subjects: Recruiting 167 asthma participants who received Tian Jiu Therapy under the primary study of HKCTR-1128. All subjects should be above age 13 and receive the same Tian Jiu Therapy, 3 times per year from 2013 to 2015. A one-year follow-up after the last Tian Jiu treatment will be conducted. Study instruments: Modern USB PC-based Spirometer and Fingertip Pulse Oximeter. Interventions: Plastering some stimulating Chinese herbal cubes on certain acupoints in the three hottest days of each year, for three consecutive years. Main outcome measures: Pulmonary Function Test, Blood Oxygen Test, Quality of Life and Standardized Questionnaire on asthma attack and symptoms will be administered before treatment, after treatment of each year and one-year follow-up after the last treatment. Data analysis: All the parameters will be analyzed, the physical improvement (Cured, Remarkably effective, Effective and Ineffective) will be recorded, and the differences in different treatment courses will be investigated and compared with previous data obtained in the primary study of HKCTR-1128 by using standard statistical analysis. Expected results: The effect of Tian Jiu Therapy on Asthma is not only immediate but also long-term and will be gradually accumulated. The Tian Jiu Therapy will acquire better efficacy on asthma if this treatment was conducted more years continuously.


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date August 31, 2021
Est. primary completion date August 31, 2016
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria: - History of Asthma Diagnostic Criteria of Asthma according to U.S.DHHS(2007): 1. Episodic symptoms of airflow obstruction 2. Difficulty breathing 3. Chest tightness 4. Cough (worse at night) 5. Symptoms occurring or worsening at night, awakening the patient 6. Symptoms occurring or worsening with exercise, viral infections, changes in weather, strong emotions, or mens; or in the presence of animals, dust mites, mold, smoke, pollen, or chemicals 7. Wheezing 8. Airflow obstruction at least partially reversible Medically stable and acute medical care does not require. E.g. intensive monitoring, invasive ventilation, haemoid-dialysis, cardiac support. Exclusion Criteria: 1. Patients currently experiencing Acute asthma attack 2. Infants and child under thirteen years old 3.Pregnant women 4. Patients with 1. Fever and pharyngitis 2. Tuberculosis 3. Severe cardiac and pulmonary diseases 4. Diabetes Mellitus 5. Hypersensitive skin condition 6. Allergy to topical medication 7. Keloid 8. Bleeding disorders 9. Severe heart diseases and with pacemaker.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tian Jiu Therapy


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Outcome

Type Measure Description Time frame Safety issue
Primary The change in Quality of life The change in Quality of life (SF-36 score) baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Primary The change in the frequency of asthma attack The change in the frequency of asthma attack baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Primary The change in admission to hospital The change in admission to hospital baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Primary The change in AE visit The change in AE visit baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Primary The change in clinic visit The change in clinic visit baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Secondary The change of Pulmonary Function (FEV1) The change of Pulmonary Function (FEV1) baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
Secondary The change of Pulmonary Function (FEV1/FEC) The change of Pulmonary Function (FEV1/FEC) baseline, change from baseline at 1-2th week; change from baseline at 12 months after treatment
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device